Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
77.1M
-
Number of holders
-
118
-
Total 13F shares, excl. options
-
42.3M
-
Shares change
-
-265K
-
Total reported value, excl. options
-
$375M
-
Value change
-
-$3.62M
-
Put/Call ratio
-
0.01
-
Number of buys
-
60
-
Number of sells
-
-50
-
Price
-
$8.88
Significant Holders of Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) as of Q1 2023
137 filings reported holding NRIX - Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q1 2023.
Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) has 118 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 42.3M shares
of 77.1M outstanding shares and own 54.86% of the company stock.
Largest 10 shareholders include BlackRock Inc. (4.29M shares), BAKER BROS. ADVISORS LP (3.88M shares), WASATCH ADVISORS LP (3.17M shares), Deep Track Capital, LP (3M shares), Redmile Group, LLC (2.75M shares), VANGUARD GROUP INC (2.62M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.58M shares), ARK Investment Management LLC (2.24M shares), STATE STREET CORP (2.24M shares), and Bain Capital Life Sciences Investors, LLC (1.82M shares).
This table shows the top 118 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.